Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE PD01A With Regard to Safety/Tolerability, Immunological Plus Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008

Trial Profile

Phase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE PD01A With Regard to Safety/Tolerability, Immunological Plus Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Affitope PD01 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors AFFiRiS
  • Most Recent Events

    • 07 Sep 2016 Results (n=28) published in an AFFiRiS media release.
    • 07 Sep 2016 According to an AFFiRiS media release, this study was funded by a $US1.04 million grant from the Michael J. Fox Foundation for Parkinson's research.
    • 14 Aug 2015 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top